CELC

Celcuity Inc

• Reuters·04/02 20:07

  Celcuity director Richard E. Buller disposes CELC shares worth 0.3 million

• TipRanks·03/27 10:57

  H.C. Wainwright Sticks to Their Hold Rating for Celcuity (CELC)

• TipRanks·03/27 00:26

  Celcuity’s Earnings Call: Big Data, Bigger Ambitions

• TipRanks·03/26 17:35

  Celcuity Buy Rating Backed by Strong Gedatolisib Data, Upcoming VIKTORIA-1 Catalyst, and Favorable Risk-Reward

• Dow Jones·03/26 15:08

  Celcuity Is Maintained at Buy by Stifel

• Benzinga·03/26 14:58

  Stifel Maintains Buy on Celcuity, Raises Price Target to $125

• TipRanks·03/26 14:50

  Celcuity price target raised to $141 from $108 at Craig-Hallum

• Dow Jones·03/26 12:30

  Celcuity Price Target Maintained With a $122.00/Share by Needham

• Benzinga·03/26 12:19

  Needham Reiterates Buy on Celcuity, Maintains $122 Price Target

• NASDAQ·03/26 11:10

  Celcuity Posts Wider FY25 Loss, Highlights Progress Toward Potential Gedatolisib Launch

• TipRanks·03/26 11:01

  Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Maze Therapeutics, Inc. (MAZE)

• TipRanks·03/26 10:45

  Celcuity: Clinical Momentum, Strong Balance Sheet, and Regulatory Catalysts Underpin Buy Rating and $122 Target

• TipRanks·03/26 10:35

  Celcuity price target raised to $125 from $115 at Stifel

• Reuters·03/26 10:34

  CELCUITY INC <CELC.O>: STIFEL RAISES TARGET PRICE TO $125 FROM $115

• Seeking Alpha·03/26 00:16

  Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations